Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer.
Jiang DM, Parshad S, Zhan L, Sim HW, Siu LL, Liu G, Shapiro JD, Price TJ, Jonker DJ, Karapetis CS, Strickland AH, Zhang W, Jeffery M, Tu D, Ng S, Sabesan S, Shannon J, Townsend A, O'Callaghan CJ, Chen EX. Jiang DM, et al. Among authors: chen ex. Clin Colorectal Cancer. 2023 Dec;22(4):457-463. doi: 10.1016/j.clcc.2023.08.006. Epub 2023 Aug 23. Clin Colorectal Cancer. 2023. PMID: 37704538 Free article. Clinical Trial.
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status.
Bahl M, Siu LL, Pond GR, Kim J, Tannock IF, Bayley A, Cummings BJ, Waldron J, Ringash J, Chen EX, Gitterman L, Lemon B, O'Sullivan B. Bahl M, et al. Among authors: chen ex. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1127-36. doi: 10.1016/j.ijrobp.2004.05.011. Int J Radiat Oncol Biol Phys. 2004. PMID: 15519784
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.
Chen EX, Batist G, Siu LL, Bangash N, Maclean M, McIntosh L, Miller WH Jr, Oza AM, Lathia C, Petrenciuc O, Seymour L. Chen EX, et al. Invest New Drugs. 2005 Oct;23(5):455-65. doi: 10.1007/s10637-005-2905-1. Invest New Drugs. 2005. PMID: 16133797 Clinical Trial.
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK; Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Goss G, et al. Among authors: chen ex. Cancer Chemother Pharmacol. 2006 Nov;58(5):703-10. doi: 10.1007/s00280-006-0201-1. Epub 2006 Mar 10. Cancer Chemother Pharmacol. 2006. PMID: 16528532 Clinical Trial.
220 results